We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

127 hedge funds and large institutions have $957M invested in Aclaris Therapeutics in 2022 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 48 increasing their positions, 26 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

217% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 6

85% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 26

12% more capital invested

Capital invested by funds: $851M → $957M (+$106M)

10% more funds holding

Funds holding: 115 → 127 (+12)

1% more call options, than puts

Call options by funds: $362K | Put options by funds: $357K

0.32% more ownership

Funds ownership: 95.03% → 95.35% (+0.32%)

0% more funds holding in top 10

Funds holding in top 10: 9 → 9 (0)

Holders
127
Holders Change
+12
Holders Change %
+10.43%
% of All Funds
2.19%
Holding in Top 10
9
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.16%
New
19
Increased
48
Reduced
26
Closed
6
Calls
$362K
Puts
$357K
Net Calls
+$5K
Net Calls Change
-$250K

Top Buyers

1
O
OrbiMed
New York
+$6.82M
2
Walleye Capital
Walleye Capital
New York
+$4.25M
3
Charles Schwab
Charles Schwab
California
+$3.91M
4
Citadel Advisors
Citadel Advisors
Florida
+$2.6M
5
BlackRock
BlackRock
New York
+$2.21M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$22.8M
2
Renaissance Technologies
Renaissance Technologies
New York
-$2.28M
3
LCM
Laurion Capital Management
New York
-$2.13M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$1.55M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.53M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$75.7M +$2.21M +140,382 +3%
VA
2
VR Adviser
New York
$71.8M – – –
RCM
3
RA Capital Management
Massachusetts
$69.2M – – –
BI
4
BVF Inc
California
$62.6M – – –
RSCM
5
Rock Springs Capital Management
Maryland
$62.4M +$537K +34,100 +0.9%
Wellington Management Group
6
Wellington Management Group
Massachusetts
$54.4M -$22.8M -1,447,410 -30%
Vanguard Group
7
Vanguard Group
Pennsylvania
$46.1M +$1.86M +118,024 +4%
FCMI
8
Foresite Capital Management IV
California
$44.2M – – –
CC
9
Commodore Capital
New York
$37.9M – – –
Holocene Advisors
10
Holocene Advisors
New York
$32.4M – – –
Point72 Asset Management
11
Point72 Asset Management
Connecticut
$29.2M +$1.88M +119,351 +7%
LCM
12
Laurion Capital Management
New York
$20.5M -$2.13M -135,451 -9%
State Street
13
State Street
Massachusetts
$20.5M +$1.15M +72,786 +6%
FCMV
14
Foresite Capital Management V
California
$19.8M – – –
Renaissance Technologies
15
Renaissance Technologies
New York
$18.7M -$2.28M -144,500 -11%
Deutsche Bank
16
Deutsche Bank
Germany
$18.4M -$91.4K -5,804 -0.5%
Fidelity Investments
17
Fidelity Investments
Massachusetts
$18M -$1.53M -96,969 -8%
TCM
18
TCG Crossover Management
California
$18M – – –
Citadel Advisors
19
Citadel Advisors
Florida
$17.6M +$2.6M +165,345 +17%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$16.2M +$1.13M +71,507 +7%
GPP
21
Great Point Partners
Connecticut
$16M -$1M -63,718 -6%
VC
22
Vivo Capital
California
$14.1M – – –
Adage Capital Partners
23
Adage Capital Partners
Massachusetts
$11M +$1.18M +75,000 +12%
WP
24
Woodline Partners
California
$11M +$1.19M +75,450 +12%
SB
25
Samsara BioCapital
California
$11M – – –
1
2 3 4 5

ACRS Hedge Fund Activity: Q3 2022 in Review

127 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q3 2022, worth a combined $957M — up 12% from $851M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new ACRS positions and 6 closed out — a net gain of 13 holders — while 48 added to existing stakes and 26 trimmed.

The largest buyer was OrbiMed, adding an estimated $6.82M. The largest seller was Wellington Management Group, cutting an estimated $22.8M.

  • 127 institutional investors held Aclaris Therapeutics (ACRS) as of Q3 2022, up from 115 in Q2 2022.
  • Funds reported $957M of Aclaris Therapeutics stock for Q3 2022, up 12% quarter-over-quarter.
  • 19 funds opened new Aclaris Therapeutics positions in Q3 2022 and 6 closed out, a net change of +13 holders.
  • The largest Aclaris Therapeutics buyer in Q3 2022 was OrbiMed, an estimated $6.82M added.
  • The largest Aclaris Therapeutics seller in Q3 2022 was Wellington Management Group, an estimated $22.8M sold.

Based on aggregated 13F filings for Q3 2022.